Efficacy and Safety of Liraglutide 3.0 mg in Patients with Overweight and Obese with or without Diabetes: A Systematic Review and Meta‐Analysis
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Background. Liraglutide in a 3.0 mg subcutaneous dose daily is approved for weight reduction. Objectives. Objectives are to evaluate the efficacy and safety of liraglutide 3.0 mg in patients with overweight and obesity irrespective of diabetic status. Methods. We conducted an electronic database search in PubMed, Embase, and https://ClinicalTrial.gov to identify all randomized control trials (RCTs) that evaluated the efficacy and safety of liraglutide 3.0 mg dose compared to placebo in overweight (≥27 kg/m 2) and obese (≥30 kg/m 2) patients above 18 years of age. Results. We compared the pooled estimate of the study results between liraglutide 3.0 mg groups and placebo groups both in diabetic and nondiabetic patients. The efficacy outcomes that were found to be significant among respective studies involving nondiabetic patients vs. diabetic patients were mean change in body weight from baseline: 12 studies [MD = −5.04 kg (95% CI = −5.60, −4.49), P < 0.001, I2 = 92.95%] vs. 2 studies [MD = −4.14 kg (95% CI = −4.95, −3.32), P < 0.001, I2 = 0%], reduction in waist circumference from baseline: 8 studies [MD = −3.64 cm (95% CI = −4.43, −2.85), P < 0.001, I2 = 96.5%] vs. 2 studies [MD = −3.11 cm (95% CI = −3.88, −2.34), P < 0.001, I2 = 0%], BMI reduction from baseline: 5 studies [MD = −1.95 kg/m 2 (95% CI = −2.22, −1.68) vs. 1 study [MD = −1.86 kg/m 2 (95% CI = −2.14, −1.57), P < 0.001, I2 = 0%, P < 0.001, I2 = 95.6%], proportion of patients losing more than 5% of weight loss from baseline: 8 studies [RR = 2.21, (95% CI = 1.89, 2.58), P = 0.03, I2 = 59.02%] vs. 2 studies [RR = 2.34, (95% CI = 1.93, 2.85), P = 0.39, I2 = 0.00%], and 10% weight loss from baseline: 7 studies [RR = 3.36, (95% CI = 1.92, 5.91), P = 0.00, I2 = 87.03%] vs. 2 studies [RR = 3.64, (95% CI = 2.46, 5.40), P = 0.81, I2 = 0.00%]. Safety outcome assessment with use of liraglutide 3.0 mg compared with placebo in respective nondiabetic vs. diabetic patients revealed significant proportion of patients experiencing the adverse events: 9 studies [RR = 1.11, (95% CI = 1.04, 1.18), P = 0.00 I2 = 79.15%] vs. 2 studies [RR = 1.06, (95% CI = 1.01, 1.11), P = 0.42, I2 = 0.03%] but similar risk of serious adverse events: 9 studies [RR = 1.03, (95% CI = 0.70, 1.51), P = 0.26, I2 = 18.54%] vs. 2 studies [RR = 1.11, (95% CI = 0.67, 1.84), P = 0.25, I2 = 23.77%] and TDAEs: 4 studies [RR = 0.89, (95% CI = 0.35, 2.28), P = 0.03, I2 = 61.89%] vs. 1 study [RR = 2.53, (95% CI = 1.00, 6.37)]. However, the pooled estimates irrespective of the glycaemic status were mean change in body weight from baseline: 14 RCT [MD = −4.91 kg (95% CI = −5.43, −4.39), P < 0.001, I2 = 92.35%], reduction in waist circumference from baseline: 10 studies [MD = −3.55 cm, (95% CI = −4.21, −2.89), P < 0.001, I2 = 94.99%], BMI reduction from baseline: 6 studies [MD = −1.86 kg/m 2, (95% CI = −2.14, −1.57), P < 0.001, I2 = 96.14%], and proportion of patients losing more than 5% and 10% of weight from baseline: [RR = 2.23, (95% CI = 1.98, 2.52), P < 0.001, I2 = 48.87%] and [RR = 3.28, (95% CI = 2.23, 4.83), P < 0.001, I2 = 78.98%], respectively. Also, the proportion of patients experiencing the adverse event was more with liraglutide 3.0 mg compared with placebo 11 study [RR = 1.09, (95% CI = 1.04, 1.15), P < 0.01, I2 = 76.60%] and similar risk for both serious adverse events: 11 studies [RR = 1.09, (95% CI = 1.04, 1.15), P < 0.01, I2 = 76.60%] and TDAEs: 5 studies [RR = 1.14, (95% CI = 0.50, 2.60), P < 0.01, I2 = 64.93%] with liraglutide compared with placebo. Conclusions. Liraglutide in 3.0 mg subcutaneous dose demonstrated significant weight reduction with a reasonable safety profile for patients with overweight or obesity regardless of diabetic status compared to placebo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures











Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Excess visceral adipose tissue can pose a threat to cardiovascular health and is linked to worsening cardiovascular biomarkers.28,29”
From Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: A systematic review and meta-analysis (2025) · cites this paper as [28]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Since waist circumference is not proportional to weight and BMI regain for semaglutide and liraglutide, this could mean that although weight is regained, the adipose tissue may be dispersed in other forms, for instance as visceral, not subcutaneous, causing the appearance of waist circumference gain to be less apparent.28”
From Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: A systematic review and meta-analysis (2025) · cites this paper as [28]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n71 · Cited by 108,283
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139 · cited 1×
“[21].”
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722 · cited 1×
“)e publication bias was assessed by using Egger’s test and presented by using a funnel plot [22].”
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552 · cited 1×
“)e pooled risk ratios (RR) and 95% confidence intervals (CI) were calculated by using a random-effects model (restricted maximum likelihood [REML] method) for both efficacy and safety outcomes which were categorical variables [20].”
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J., Bossuyt, P., Boutron, I., Hoffmann, T., mulrow, C., Shamseer, L., Tetzlaff, J., Akl, E., Brennan, S. E., et al. (2020) · doi:10.31222/osf.io/v7gm2 · Cited by 5,177
Guh, D. P., Zhang, W., Bansback, N., Amarsi, Z., Birmingham, C. L., & Anis, A. H. (2009) · BMC Public Health · doi:10.1186/1471-2458-9-88 · Cited by 3,855
European Guidelines for Obesity Management in Adults
Yumuk, V., Tsigos, C., Fried, M., Schindler, K., Busetto, L., Micic, D., & Toplak, H. (2015) · Obesity Facts · doi:10.1159/000442721 · Cited by 3,432
Poirier, P., Giles, T. D., Bray, G. A., Hong, Y., Stern, J. S., Pi-Sunyer, F. X., & Eckel, R. H. (2006) · Circulation · doi:10.1161/circulationaha.106.171016 · Cited by 3,165
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724 · cited 8×
“Overall, the included studies showed an acceptable methodological quality, with six of them being of excellent quality [25, 26, 28, 33, 35, 37].”
InfluentialLevesque, R. J. R. (2018) · Encyclopedia of Adolescence · doi:10.1007/978-3-319-33228-4_447 · Cited by 1,657
Research works printed but not linked: 2
- 2021 https://training.cochrane.org/handbook/current/chapter-08
- https://training.cochrane.org/handbook/current/chapter-13
Cited by
Berg, S., Stickle, H., Rose, S. J., & Nemec, E. C. (2025) · Obesity Reviews · doi:10.1111/obr.13929 · Cited by 111
“11,31,32 Similarly, readers can review original body habitus changes to compare outcomes by examining the “ GLP-1 Treatment ” columns of each forest plot.”
Ketogenic Diets for Body Weight Loss: A Comparison with Other Diets
Dyńka, D., Rodzeń, Ł., Rodzeń, M., Pacholak-Klimas, A., Ede, G., Sethi, S., Łojko, D., Bartoń, K., Berry, K., Deptuła, A., et al. (2025) · Nutrients · doi:10.3390/nu17060965 · Cited by 47
“Maladaptive behaviour pa tt erns of cycling, such as a greater number of past weight loss a tt empts, weight gain, a greater desire to lose weight, and even”
Liu, L., Shi, H., Xie, M., Sun, Y., & Nahata, M. C. (2024) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-024-01779-x · Cited by 43
Pharmacological Treatments and Natural Biocompounds in Weight Management
Gasmi, A., Mujawdiya, P. K., Nehaoua, A., Shanaida, M., Semenova, Y. M., Piscopo, S., Menzel, A., Voloshyn, V., Voloshyn, O., Shanaida, V., et al. (2023) · Pharmaceuticals · doi:10.3390/ph16020212 · Cited by 24
“0 mg subcutaneously in obese patients [46].”
New Insights into the Use of Liraglutide—Impact on Cardiovascular Risk and Microvascular Outcomes
Wronka, M., Krzemińska, J., Młynarska, E., Rysz, J., & Franczyk, B. (2023) · Biomedicines · doi:10.3390/biomedicines11041159 · Cited by 25
“[52] The SCALE study [53] Konwar et al.”
BackgroundMethodInfluentialSchmidt, P. H. S., Pasqualotto, E., dos Santos, H. V., de Souza, L. S. N., dos Santos, B. E., Chavez, M. P., Ferreira, R. O. M., Hohl, A., Ronsoni, M. F., & van de Sande-Lee, S. (2025) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2025.01.009 · Cited by 18
Liu, L., Cui, J., Neidecker, M. V., & Nahata, M. C. (2025) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2025.31.5.441 · Cited by 33
Zamanian, N., Imani, H., Talebi, S., Rahimlou, M., Khosroshahi, R. A., & Mohammadi, H. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177966 · Cited by 19
Khawaji, A., A. Jaly, A., A. Bakri, H., Ravi, R., Hattan, A., Khawaji, A., & Najmi, W. (2025) · Journal of Obesity · doi:10.1155/jobe/3442754 · Cited by 13
Self-citationThe effect of obesity interventions on male fertility: a systematic review and meta-analysis
Peel, A., Lyons, H. E., Tully, C. A., Vincent, A. D., Jesudason, D. R., Wittert, G., & McPherson, N. O. (2025) · Human Reproduction Update · doi:10.1093/humupd/dmaf025 · Cited by 19
Tirzepatide: A New Generation Therapeutic for Diabetes Type 2
Al‐Horani, R. A., & Chedid, M. (2022) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530322666221004151212 · Cited by 15
Grannell, A., Al‐Najim, W., & le Roux, C. (2024) · Clinical Obesity · doi:10.1111/cob.12622 · Cited by 10
GLP-1 Receptor Agonists and Noncardiometabolic Outcomes: An Umbrella Review of Meta-Analyses
Yang, K., Liu, C., Guo, Q., & Li, Y. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.4722 · Cited by 15
Silva, I. D. S., Souza, L. P., Pereira, P. G., de Carvalho, J. J., Moreno, A. M., Castro-Faria-Neto, H. C., Siqueira, R. D. A., d’Avila, J. C., & Carlos, A. S. (2022) · Journal of Endocrinology and Metabolism · doi:10.14740/jem843 · Cited by 9
“trol and body weight combined with cardioprotection and is considered a safe drug to treat diabetes, obesity, and related cardiometabolic disorders [10].”
BackgroundDorneles, G. P., Algeri, E. D. B. D. O., Lauterbach, G., Pereira, M. G., & Fernandes, B. (2024) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2303-8558 · Cited by 9
“It is crucial to emphasize that a consistent and clinically significant reduction in body weight plays a pivotal role in enhancing metabolic health and addressing other comorbidities associated with obesity [36, 37].”
BackgroundResultGlucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs): A Pan-Steatotic Liver Disease Treatment?
Chrysavgis, L., Mourelatou, N. G., & Cholongitas, Ε. (2025) · Biomedicines · doi:10.3390/biomedicines13071516 · Cited by 10
“Agents such as liraglutide (3.0 mg/day) [32] and semaglutide (2.4 mg/week) [28] have been shown to produce substantial weight loss in patients with or without diabetes.”
InfluentialThe efficacy of liraglutide combined with intragastric balloon on weight loss
Yılmaz, A., Hanlioğlu, S., Demiral, G., & Karatepe, O. (2023) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.20230571 · Cited by 9
“Subcutaneous use of liraglutide has been found to be successful for weight loss in adults and approved for overweight and obese in combination with reduced calorie foods and regular physical activity 5 .”
BackgroundLu, T., Liu, B., Ge, L., Liu, Y., & Yu, L. (2025) · International Journal of Obesity · doi:10.1038/s41366-025-01719-3 · Cited by 10
Efficacy and safety of incretin co-agonists: Transformative advances in cardiometabolic healthcare
Bhat, S., Fernandez, C. J., Lakshmi, V., & Pappachan, J. M. (2025) · World Journal of Cardiology · doi:10.4330/wjc.v17.i8.107991 · Cited by 9
Differential Efficacy of Weight Loss Interventions in Patients with Versus Without Diabetes
Losada-Díaz, F., Lizarazo-Bocanegra, S., Perdomo-Lugo, J. J., Gutiérrez-Romero, S. A., Correa-Osio, I., & Mendivil, C. O. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01646-y · Cited by 11
Obesity vs. Metabolically Healthy Obesity in East Asia
Mathis, B. J., Tanaka, K., & Hiramatsu, Y. (2023) · Encyclopedia · doi:10.3390/encyclopedia3020053 · Cited by 8
“Furthermore, studies of glucose-controlling drugs that result in smaller waistline circumference and large population studies have observed decreased odds ratios of diabetic and cardiovascular risks after moderate weight loss [14,18].”
BackgroundAlsanea, S., Alkofide, H., Almadi, B., Almohammed, O. A., Alwhaibi, A. M., Alrabiah, Z., & Kalagi, N. A. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.05.009 · Cited by 5
Gratzke, M., von Bueren, J., Garrahy, E., Calewaert, B., Abeck, F., & Wuelfing, C. (2025) · Digital Health · doi:10.1177/20552076251382040 · Cited by 3
Wang, C., Li, K.-X., Sun, S.-Q., & Liu, T.-C. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1629741 · Cited by 3
Joshi, S., Das, A. K., Khunti, K., Khunti, S., & CHOUDHARI, S. Y. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s570273 · Cited by 3
Łukaszewicz, A., Gołaszewski, P., Nadolny, K., Łukaszewicz, J., Ładny, J. R., & Hady, H. R. (2022) · Medical Research Journal · doi:10.5603/mrj.a2022.0055 · Cited by 2
“86 kg/m2 BMI with a reasonable safety profile [29].”
BackgroundLiu, L., Nahata, M., Shi, H., Sun, Y., & Xie, M. (2024) · Research Square · doi:10.21203/rs.3.rs-4184273/v1 · Cited by 2
Injections for weight loss: what’s new in GLP-1 RAs for obesity treatment – review
Zajac, M., Zaucha, R., Silldorff, J., Anczyk, S., Dudek, M., Fura, T., Felińska, Z., Iszczuk, O., Gajkiewicz, M., & Jaskółka, M. (2024) · Quality in Sport · doi:10.12775/qs.2024.20.53875 · Cited by 1
“Clinical trials have demonstrated that the use of both medications is associated with significant weight loss in adults with overweight or obesity [19-21].”
BackgroundRelationship between hyperleptinemia and cardiometabolic risk in persons with obesity
Chernyavska, I. V., Кравчун, Н. А., Дунаєва, І., Tykha, I. A., Oliynikova, S. P., & Rassolova, O. S. (2024) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.20.1.2024.1358 · Cited by 2
Łukaszewicz, A., Głuszyńska, P., Hady, Z. R., Pawłuszewicz, P., Łukaszewicz, J., & Hady, H. R. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13195662 · Cited by 2
Pharmacotherapeutics efficacy in obesity treatment: A systematic review
Tarboush, B. A., Karali, H. F., Zaigham, M. T., Ibrahim, G., & Farhad, E. S. (2023) · International Journal of Advanced Community Medicine · doi:10.33545/comed.2023.v6.i1a.256
Andrade, L. J. D. O., de Oliveira, G. C. M., de Oliveira, L. C. M., Bittencourt, A. M. V., & de Oliveira, L. M. (2023) · Research Square · doi:10.21203/rs.3.rs-3464228/v1
Evaluation of the Effectiveness of Liraglutide on Metabolic Parameters in the Treatment of Obesity
Akkurt, A. (2023) · Cureus · doi:10.7759/cureus.50544 · Cited by 1
“In a meta-analysis, Konwar et al. included approximately 6000 patients who did not have DM but were obese and using LG and observed 2.8-11.8 kg of BWL in their follow-up at 12-56 weeks [18].”
MethodInfluentialWang, X., He, K., Li, J., Liu, Y., Peng, Z., Zhao, L., & Ji, S. (2024) · Cellular and Molecular Biology · doi:10.14715/cmb/2024.70.2.22
Impact of Nutrient-Stimulated Hormone (NUSH) Dynamics on Body WeightPreprint
Andrade, L. J. D. O., de Oliveira, G. C. M., de Oliveira, L. C. M., Bittencourt, A. M. V., & de Oliveira, L. M. (2024) · Research Square · doi:10.21203/rs.3.rs-4013174/v1
Andrade, L. J. D. O., de Oliveira, L. C. M., Bittencourt, A. M. V., Silva, C. P., de Oliveira, L. M., & de Oliveira, G. C. M. (2025) · medRxiv · doi:10.1101/2025.07.06.25330959
Panhofer, P., Krzyzanowska-Mittermayer, K., & Rothe, S. (2026) · Deutsche Zeitschrift für Akupunktur · doi:10.1007/s42212-025-00797-8
Clinical and metabolic profile of adults with obesity attending lifestyle medicine clinics
AlTaib, H., AlAqeel, R., Arafat, A. A., Kunnathodi, F., Alshaikh, A., & Alotaibi, H. F. (2026) · PLoS ONE · doi:10.1371/journal.pone.0342153
Teofilović, B. D., Trkulja, J., Grujić-Letić, N. N., Gligorić, E. I., Baletic, D., Tomić, L., Mesarović, A., & Rašković, A. (2026) · Current Medical Research and Opinion · doi:10.1080/03007995.2026.2727202
Bawadi, H. A., Abuhijleh, H., Nofal, M., Zakaria, Z. Z., & Al‐Asmakh, M. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70338
Himali, N. A., Al-Habsi, H., Mushrafi, A. A., Shidi, A. A., Abbas, A., Kindi, A. A., Sayid, H., Mohammadi, I., Subhi, A. A., & Kiyumi, M. H. A. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15207797
“Liraglutide is given by daily subcutaneous injection at doses up to 3.0 mg for weight management [6,7].”
Influential
Metadata
- Authors
- Konwar, M., Bose, D., Jaiswal, S. K., Maurya, M. K., & Ravi, R.
- Affiliations
- King Edward Memorial Hospital and Seth G.S. Medical College (IN)
- Jazan University (SA)
- Corresponding author
- Ravi, Renju
- Venue
- International Journal of Clinical Practice
- Publisher
- Wiley
- Published
- 2022-01
- Volume
- 2022
- Issue
- 1
- Pages
- 1201977-1201977
- ISSN
- 1368-5031 (ISSN-L)
- 1742-1241
- PMC
- PMC9325632
- OpenAlex
- W4286213365
- Cited by
- 41
- References
- 47
- Citations by year
- 2026: 7 · 2025: 13 · 2024: 10 · 2023: 8 · 2022: 3
- FWCI
- 1.22
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- International Journal of Clinical Practice (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- liraglutide, GLP-1 receptor agonists, obesity, overweight, weight loss, type 2 diabetes, waist circumference, BMI reduction, adverse events, drug safety, placebo comparison
- MeSH terms
- Liraglutide, Diabetes Mellitus, Humans, Obesity, Weight Loss, Overweight
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.